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Background
The current article is a systematic registration and
meta-analysis of the available clinical trials concerning
the usefulness of aripiprazole in the treatment of bipolar
disorder in affective as well as in psychotic symptoms.
Materials and methods
A systematic MEDLINE and repositories search con-
cerning treatment guidelines and clinical trials for aripi-
prazole in bipolar disorder.
Results
The pooled effect size for acute manic symptoms was
equal to 0.34. The NNT was 6 for aripiprazole vs pla-
cebo concerning response at week 3 and equal to 14
concerning remission. The average day response started
was day 3. The suicide rates were negligible for all
groups. In contrast to the individual isolated trials, the
meta-analysis for acute bipolar depression suggests a
significant difference at week 8 with an effect size 0.17.
The meta-analysis of the 4 trials which reported the effi-
cacy of aripiprazole on psychotic symptoms during an
acute manic/mixed episodes suggests that the effect size
vs. placebo was equal to 0.14 but a more reliable and
accurate estimation is 0.18 for the total PANSS score.
The effect was higher for the PANSS positive subscale
(0.28), PANSS hostility subscale (0.24) and PANSS cog-
nitive subscale (0.20), and lower for the PANSS negative
(0.12). No data on the psychotic symptoms during the
depressive phase of bipolar illness exist. The mainte-
nance data suggest that the median survival time for the
emergence of a manic episode for the aripiprazole group
was not evaluable, while the median survival time for
placebo was 118-203 days depending on the clinical sub-
population. Concerning psychotic symptoms, at week 26
all except the total PANSS score showed a significant
superiority of aripiprazole over placebo (d = 0.28 for
positive, d = 0.38 for the cognitive and d = 0.71 for the
hostility subscales) and at week 100 the results were
similar (d = 0.42, 0.63 and 0.48 respectively).
Conclusion
T h ed a t aa n a l y s e df o rt h ec u r r e n ts t u d ys u p p o r tt h e
usefulness of aripiprazole during all phases of bipolar
illness, inspite of the rather weak effect on depression
and that the efficacy during the maintenance period is
proven against new manic episodes and in patients with
an index manic episode who responded to aripiprazole
during the acute phase.
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